Loading...
Loading...
In a report published Monday, J.P. Morgan reiterated its Overweight rating on Clovis Oncology
CLVS, and raised its price target from $18.00 to $33.00.
J.P. Morgan noted, “We are reiterating our OW rating on CLVS and bumping our target to $33 (from $18) post the recent 4Q report as well as a detailed follow-up call with management. Based on this discussion, we are increasingly optimistic that both of the company's clinical stage oncology candidates – CO-1686 and rucaparib – will have encouraging updates at ASCO this year, as well as at other medical conferences this Fall. With an eventful 2013 upcoming and the potential to have two fully owned oncology assets in pivotal programs within 12-15 months, we recommend investors remain buyers of CLVS.”
Clovis Oncology closed on Friday at $26.05.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in